Admedus To Launch Cardiocel Product For Vascular Repair
• CardioCel® product range now includes three products sizes
• CardioCel to be used in vascular repairs
Brisbane, Australia May 18th, 2015
Admedus Limited (ASX: AHZ) today announced that it would launch a new CardioCel® product into the US market in June 2015. The new product will be a 2cm X 8cm tissue patch for vascular repairs such as carotid endarterectomies.
The new CardioCel product launch is part of the Company’s strategy to expand the use of CardioCel across a range of surgical applications.
“The new CardioCel product is part of Admedus’ plan to build an ADAPT™ Tissue franchise, providing surgeons with a range of products for surgical repairs,” said Admedus CEO Mr Lee Rodne.
In addition to the use of CardioCel for cardiac repairs and reconstructions, the Company also announced that CardioCel has been successfully used in 10 US cases of vascular repair, including carotid endarterectomies and femoral artery repairs. The use of CardioCel in vascular applications is within the current indication for the USA.
The vascular repair market represents a significant potential market with an estimated 180,000 carotid endarterectomies performed each year in the USA.
“The Admedus sales team continues to expand the number of centers using CardioCel and this new product size will help to support broader market adoption and momentum in our sales program, which we anticipate will support further revenue growth in the coming year and beyond,” said Mr Rodne CardioCel is currently used in 31 European and 35 US centers and over 70 centers globally. Over 1800 patients have been implanted with CardioCel.
Follow us:
Twitter: @Admedus
Facebook: www.facebook.com/pages/Admedus
For more information, please contact:
Dr Julian Chick | Chief Operating Officer | Admedus Limited
Tel: +61 3 9620 5454
Media:
Haley Price
+61 (0) 423 139 163
hprice@admedus.com
Media Europe & Asia
Consilium Strategic Communications
Jessica Hodgson / Ivar Milligan
+44 (0)20 3709 5700
admedus@consilium-comms.com
About Admedus Limited
Admedus (ASX: AHZ) is a diversified, global healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.
Admedus has commercialised its innovative tissue engineering technology for regenerative medicine in four continents. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.
Further information on the company can be found on www.admedus.com
About CardioCel®
CardioCel® is a type of cardiovascular bio-scaffold that can be used to repair congenital heart deformities and more complex heart defects.
It is used to repair diseased paediatric and adult hearts. These repairs range from routine hole-in-the-heart operations to major vessel outflow tract repairs. The CardioCel® scaffold may also be used to repair heart valves. CardioCel® has been shown to allow tissue regeneration once implanted. Some researchers postulate that stem cells play an active role in tissue regeneration, suggesting that the product facilitates endogenous stem cells and other cells to regenerate and repair damaged tissue.
CardioCel® is the Admedus Group’s lead regenerative tissue bio-implant used in repairing heart defects, including the repair of heart valves. It is engineered via the Admedus Group’s proprietary ADAPT® tissue engineering process to produce a durable, collagen scaffold with handling properties preferred by surgeons that avoids calcification, while supporting native cell infiltration, growth and differentiation.
Help employers find you! Check out all the jobs and post your resume.
• CardioCel to be used in vascular repairs
Brisbane, Australia May 18th, 2015
Admedus Limited (ASX: AHZ) today announced that it would launch a new CardioCel® product into the US market in June 2015. The new product will be a 2cm X 8cm tissue patch for vascular repairs such as carotid endarterectomies.
The new CardioCel product launch is part of the Company’s strategy to expand the use of CardioCel across a range of surgical applications.
“The new CardioCel product is part of Admedus’ plan to build an ADAPT™ Tissue franchise, providing surgeons with a range of products for surgical repairs,” said Admedus CEO Mr Lee Rodne.
In addition to the use of CardioCel for cardiac repairs and reconstructions, the Company also announced that CardioCel has been successfully used in 10 US cases of vascular repair, including carotid endarterectomies and femoral artery repairs. The use of CardioCel in vascular applications is within the current indication for the USA.
The vascular repair market represents a significant potential market with an estimated 180,000 carotid endarterectomies performed each year in the USA.
“The Admedus sales team continues to expand the number of centers using CardioCel and this new product size will help to support broader market adoption and momentum in our sales program, which we anticipate will support further revenue growth in the coming year and beyond,” said Mr Rodne CardioCel is currently used in 31 European and 35 US centers and over 70 centers globally. Over 1800 patients have been implanted with CardioCel.
Follow us:
Twitter: @Admedus
Facebook: www.facebook.com/pages/Admedus
For more information, please contact:
Dr Julian Chick | Chief Operating Officer | Admedus Limited
Tel: +61 3 9620 5454
Media:
Haley Price
+61 (0) 423 139 163
hprice@admedus.com
Media Europe & Asia
Consilium Strategic Communications
Jessica Hodgson / Ivar Milligan
+44 (0)20 3709 5700
admedus@consilium-comms.com
About Admedus Limited
Admedus (ASX: AHZ) is a diversified, global healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.
Admedus has commercialised its innovative tissue engineering technology for regenerative medicine in four continents. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.
Further information on the company can be found on www.admedus.com
About CardioCel®
CardioCel® is a type of cardiovascular bio-scaffold that can be used to repair congenital heart deformities and more complex heart defects.
It is used to repair diseased paediatric and adult hearts. These repairs range from routine hole-in-the-heart operations to major vessel outflow tract repairs. The CardioCel® scaffold may also be used to repair heart valves. CardioCel® has been shown to allow tissue regeneration once implanted. Some researchers postulate that stem cells play an active role in tissue regeneration, suggesting that the product facilitates endogenous stem cells and other cells to regenerate and repair damaged tissue.
CardioCel® is the Admedus Group’s lead regenerative tissue bio-implant used in repairing heart defects, including the repair of heart valves. It is engineered via the Admedus Group’s proprietary ADAPT® tissue engineering process to produce a durable, collagen scaffold with handling properties preferred by surgeons that avoids calcification, while supporting native cell infiltration, growth and differentiation.
Help employers find you! Check out all the jobs and post your resume.